Pasteurized Akkermansia muciniphila is a clinically tractable postbiotic candidate, but its activity cannot be assigned to a single principle. Heat-stable Amuc_1100 is demonstrably retained in pasteurized cells, whereas the GLP-1-inducing protein P9, extracellular vesicles (AmEVs), membrane lipids, and diffusible metabolites are supported mainly by studies of live bacteria or isolated preparations, whose retention and activity in pasteurized products remain unestablished; together they create overlapping links between the intestinal niche and hepatic physiology. Liver-directed studies now extend this framework beyond indirect metabolic inference. In mice, pasteurized bacteria and Amuc_1100 improve steatosis and alcohol-associated liver injury, while AmEV-containing preparations attenuate experimental fibrosis. Acetate, propionate, and L-norleucine associated with Akkermansia muciniphila also engage defined hepatic metabolic or antioxidant pathways. Yet the contribution of each effector, its exposure-response relationship, and its strain dependence remain unresolved. Human studies still evaluate whole-cell preparations and report heterogeneous metabolic and weight-related outcomes rather than liver histology or validated MASLD efficacy endpoints, and they lack validated effector-level pharmacodynamic assays. Here, we integrate the evidence, define the principal causal and translational gaps, and identify experiments that could close them. Priorities include orthogonal effector deconvolution, measurement of effector exposure in stored clinical samples, and specifications that link strain and processing to potency. Purified effectors need not replace pasteurized cells. Instead, A. muciniphila should be developed as a measurable multi-effector system, allowing product format to be selected according to the indication and the evidence.
